Q-omics provides the consensus-scored SEPTIN14P8 profile across patient tissues and cancer cell-line models. SEPTIN14P8 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SEPTIN14P8 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, SEPTIN14P8 RNA expression shows 9,115 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where SEPTIN14P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEPTIN14P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEPTIN14P8 survival associations across molecular data types. SEPTIN14P8 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEPTIN14P8 RNA expression–survival associations across cancer types. High SEPTIN14P8 expression shows unfavorable associations in MESO, LUAD, LIHC, STAD and CHOL, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify MESO as the clearest survival context for SEPTIN14P8 RNA expression.
This table summarizes SEPTIN14P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SEPTIN14P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEPTIN14P8 shows lower tumor expression in KIRC and higher tumor expression in PAAD and KIRP. The KIRC box plot shows higher SEPTIN14P8 RNA expression in normal versus tumor tissue (log2 FC = −0.184, t-test p = .011).
This table shows molecular features associated with SEPTIN14P8 in patient tissues and cancer cell lines. In patient samples, SEPTIN14P8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
